This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Preventable Cause of latrogenic Theophylline Toxic Reactions

John D. Butts, PharmD; Bradley Secrest, MD; Rolando Berger, MD

Arch Intern Med. 1991;151(10):2073-2077.

Abstract
When theophylline is used for the treatment of patients with obstructive pulmonary diseases, most clinicians attempt to maintain serum levels between 55 and 110 µmol/L because higher levels are associated with an increased risk of serious toxic effects. Nonlinear theophylline kinetics are known to occur in animals, in some pediatric patients, and at very high toxic levels in adults. However, within the usual therapeutic range of serum levels, first-order kinetics are assumed to operate, and, thus, a one-compartment model or a model-independent approach is routinely used for dose adjustments. We have recently encountered two adult patients in whom nonlinear theophylline kinetics existed within the subtherapeutic and therapeutic range of serum levels. In both cases this was not immediately recognized by the clinician, resulting in prolonged use of subtherapeutic doses of theophylline. In addition, in one case our empiric attempts to achieve therapeutic serum levels resulted in serious theophylline toxicity. We present only the data from this latter patient to be used as a case study. Based on this example and a review of the literature, we propose that to avoid such a potentially fatal complication the following steps should be taken when dealing with a patient in whom serum theophylline levels fail to rise as expected with increasing oral doses: (1) supervised administration of oral theophylline to rule out noncompliance; (2) discontinuation of further empirical increases of the oral dose of theophylline; (3) obtention of steady-state serum levels on at least two different oral doses of theophylline; and (4) calculation of the appropriate maintenance dose of theophylline for that individual patient using any of the methods cited in this report.

(Arch Intern Med. 1991;151:2073-2077)

Author Affiliations
From Clinical Services, Community Hospitals, and Butler University College of Pharmacy, Indianapolis, Ind (Dr Butts); Department of Medicine (Dr Secrest) and Division of Pulmonary and Critical Care Medicine (Dr Berger), University of Kentucky College of Medicine, Albert B. Chandler Medical Centers (Drs Secrest and Berger), and the Veterans Administration (Dr Berger), Lexington, Ky.

Footnotes
Accepted for publication December 14, 1990.

Reprint requests to Pulmonary Medicine Section, VA Medical Center III-H, Lexington, KY 40511 (Dr Berger).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Continuous venovenous haemofiltration for the treatment of theophylline toxicity
Henderson et al.
Thorax 2001;56:242-243.
ABSTRACT | FULL TEXT